1. Home
  2. KBR vs TMDX Comparison

KBR vs TMDX Comparison

Compare KBR & TMDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo KBR Inc.

KBR

KBR Inc.

HOLD

Current Price

$37.22

Market Cap

5.3B

Sector

Industrials

ML Signal

HOLD

Logo TransMedics Group Inc.

TMDX

TransMedics Group Inc.

HOLD

Current Price

$114.94

Market Cap

4.6B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
KBR
TMDX
Founded
1901
1998
Country
United States
United States
Employees
N/A
N/A
Industry
Military/Government/Technical
Biotechnology: Electromedical & Electrotherapeutic Apparatus
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
5.3B
4.6B
IPO Year
2006
2019

Fundamental Metrics

Financial Performance
Metric
KBR
TMDX
Price
$37.22
$114.94
Analyst Decision
Buy
Buy
Analyst Count
8
9
Target Price
$53.14
$154.00
AVG Volume (30 Days)
1.3M
857.9K
Earning Date
05-05-2026
05-07-2026
Dividend Yield
1.81%
N/A
EPS Growth
15.05
382.18
EPS
3.21
4.87
Revenue
$5,767,000,000.00
$605,494,000.00
Revenue This Year
$4.46
$24.12
Revenue Next Year
$5.21
$18.69
P/E Ratio
$11.39
$23.20
Revenue Growth
2.27
37.13
52 Week Low
$36.33
$62.42
52 Week High
$56.78
$156.00

Technical Indicators

Market Signals
Indicator
KBR
TMDX
Relative Strength Index (RSI) 35.26 35.22
Support Level N/A $106.27
Resistance Level $45.05 $120.28
Average True Range (ATR) 1.12 7.56
MACD -0.24 -2.44
Stochastic Oscillator 15.57 12.40

Price Performance

Historical Comparison
KBR
TMDX

About KBR KBR Inc.

KBR, formerly Kellogg Brown & Root, is a global provider of technology, integrated engineering, procurement, and construction delivery, and operations and maintenance services. The company's business is organized into two segments: mission technology solutions and sustainable technology solutions. KBR has operations in over 30 countries and employs approximately 34,000 people. The firm generated $7.7 billion in revenue in 2024.

About TMDX TransMedics Group Inc.

TransMedics Group Inc is a commercial-stage medical technology company transforming organ transplant therapy for end-stage organ failure patients across multiple disease states. It has developed the Organ Care System(OCS) to comprehensively address the limitations of cold storage. The OCS is a portable organ perfusion, optimization and monitoring system that utilizes technology to replicate near-physiologic conditions for donor organs outside of the human body. The Company has developed and is commercializing a proprietary system to preserve and deliver human organs for transplant in a near-physiologic condition to address the limitations of cold storage organ preservation.

Share on Social Networks: